Sign up
Pharma Capital

Physiomics lands pre-clinical contract for virtual tumour tech

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division
tumour
Contract wlil be for pre-clinical work

Physiomics Plc (LON:PYC) has been awarded another pre-clinical contract for its Virtual Tumour technology.

The contract is worth £35,000 and with an unnamed major pharma group.

READ: Physiomics and Merck team up to progress Virtual Tumour technology

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes.

The modelling helps with efficacy and toxicity and identifies the best drug combinations. 

Jim Millen, chief executive, said: "We are delighted to be working with a significant new client.  If this initial project is successful, we would hope to develop a longer-term relationship."

In November, Physiomics completed a  human Virtual Tumour project with Merck following which it signed a master services agreement with the German pharma giant.

PhilW.jpg
Why Invest In Physiomics Plc? Read More Here

Register here to be notified of future PYC Company articles
View full PYC profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.